CellType builds on-prem LLMs trained on pharma data to simulate biological responses
david_van_dijk · x · 2026-09-25
The author frames two LLM roles in biology: co-scientist (what experiment to run) and simulator (what happens if we run it). His company CellType builds the latter: specialized LLMs trained on pharma's proprietary data, run on-prem to predict biological responses.
More from Venture
- Insight Partners maps the primary care startup landscape — HealthcareAIGuy · 2026-09-25
- Infra Play on Redpoint's 2026 market update: AI buildout still accelerating, bubble talk fades — thedealdirector · 2026-09-25
- Stripe sees record surge in new businesses at 2x last year's rate, and founders brace for a harder distribution fight — victor_explore · 2026-09-25
- Goldman: hyperscaler capex to grow 54% next year to $1.2 trillion — firstadopter · 2026-09-25
- BlackRock sees AI driving digital asset demand as agent-to-agent payments loom — tallmetommy · 2026-09-25
- Anthropic's July-31×365 Annualized Revenue Method Draw Fire as Son Predicts Labs Must IPO — whurley · 2026-09-25